Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

Apr 26, 2023

SELL
$283.23 - $323.1 $34,554 - $39,418
-122 Reduced 11.9%
903 $284,000
Q4 2022

Jan 26, 2023

SELL
$285.76 - $321.48 $11,716 - $13,180
-41 Reduced 3.85%
1,025 $0
Q3 2022

Oct 25, 2022

BUY
$273.83 - $305.53 $283,961 - $316,834
1,037 Added 3575.86%
1,066 $309,000
Q2 2022

Jul 15, 2022

SELL
$234.96 - $292.55 $95,628 - $119,067
-407 Reduced 93.35%
29 $8,000
Q1 2022

Apr 21, 2022

BUY
$221.42 - $260.97 $90,117 - $106,214
407 Added 1403.45%
436 $114,000
Q3 2021

Oct 28, 2021

BUY
$181.39 - $202.99 $5,260 - $5,886
29 New
29 $5,000
Q2 2021

Jul 27, 2021

SELL
$187.49 - $221.1 $14,249 - $16,803
-76 Closed
0 $0
Q4 2020

Feb 05, 2021

BUY
$207.01 - $276.09 $15,732 - $20,982
76 New
76 $18,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Destiny Wealth Partners, LLC Portfolio

Follow Destiny Wealth Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Destiny Wealth Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Destiny Wealth Partners, LLC with notifications on news.